Venture Funding Deals: Spin-Offs Gain Their Own Footing
Pfizer-backed SpringWorks, ProQR spin-out Amylon and Landos, the first firm out of accelerator Xontogeny, gain their own financing. Other venture rounds support Autolus, Grid Therapeutics, Excision and more.
You may also be interested in...
Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.